Fifty 410 vs MEDVi (2026): prices, structure, verdict

On tirzepatide, only MEDVi↗ has a rankable figure: $399 a month all-in; Fifty 410↗ publishes no maintenance-dose tirzepatide figure we could capture (advertised start: $133), so a like-for-like number does not exist.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only MEDVi has a rankable figure: $299 a month all-in; Fifty 410 does not offer semaglutide.

§ Side by side

§ Each record, read aloud

The two records, condensed

Fifty 410: the record, condensed

On tirzepatide, Fifty 410 advertises from $133 — and publishes no maintenance-dose figure we could capture. A starter-only price cannot be annualized, cannot be ranked, and should be treated as the bottom of an unstated range: before enrolling on its strength, get the 10 mg price in writing, and if the program will not state it, price the program at its ceiling rather than its floor.

Operationally at Fifty 410: shipping unknown; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Fifty 410 page · visit Fifty 410 ↗

MEDVi: the record, condensed

Start with the load-bearing figure: $399 a month, all-in, is what MEDVi charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $399 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #14 of 17 in the verified tirzepatide index — $184/month above the floor (NexLife↗, $215) — and sits $50 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $4,788.

MEDVi’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #18 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

§ Structure vs structure

Everything besides the price

Coverage: Fifty 410 publishes “not published”; MEDVi publishes “priced differently in CA/NC on some plans” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Fifty 410 — unknown; not published. MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate.

Evidence: Fifty 410 source-verified (captured 2026-08-05); MEDVi source-verified (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between Fifty 410 and MEDVi

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Fifty 410: not published; MEDVi: 12-month plan applies to lowest rate) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings